Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Inclusion Criteria:

• Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria

• Active SLE disease

• On stable SLE treatment regimen

Exclusion Criteria:

• Pregnant or nursing

• Have received treatment with an B cell targeted therapy

• Have received treatment with a biologic investigational agent in the past year

• Have received intravenous (IV) cyclophosphamide within 180 days of Day 0

• Have severe lupus kidney disease

• Have active central nervous system (CNS) lupus

• Have required management of acute or chronic infections with the past 60 days

• Have current drug or alcohol abuse or dependence or within the past year

• Have a historically positive test or test positive at screening for humanimmunodeficiency virus (HIV), hepatitis B, or hepatitis C

• Have a history of an allergic or anaphylactic reaction to drugs, food, or insectsrequiring medical intervention